Preview

Евразийский кардиологический журнал

Расширенный поиск

ДИАГНОСТИКА И ЛЕЧЕНИЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ

Полный текст:

Об авторах

С. П. Голицын

Россия
д.м.н


Е. П. Панченко

Россия
д.м.н


Е. С. Кропачева

Россия
к.м.н


Л. Ю. Лайович

Россия
к.м.н


Е. Б. Майков

Россия
д.м.н


Н. Ю. Миронов

Россия
к.м.н


О. О. Шахматова

Россия
к.м.н


Список литературы

1. Ревишвили А.Ш., Шляхто Е.В., Сулимов В.А., Рзаев Ф.Г., Горев М.В., Нардая Ш.Г., Шпектор А.В., Голицын С.П., Попов С.В., Шубик Ю.В., Яшин С.М., Михайлов Е.Н., Покушалов Е.А., Гиляров М.Ю., Лебедев Д.С., Андреев Д.А., Баталов Р.Е., Пиданов О.Ю., Медведев М.М., Новикова Н.А. Диагностика и лечение фибрилляции предсердий. Клинические рекомендации. М.: Всероссийское научное общество специалистов по клинической электрофизиологии, аритмологии и кардиостимуляции; 2017. 211 с.

2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, Volume 37, Issue 38, 7 October 2016, Pages 2893–2962,https://doi.org/10.1093/eurheartj/ehw210

3. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelinesand the Heart Rhythm Society. J Am CollCardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28. Review. No abstract available. Erratum in: J Am CollCardiol. 2014 Dec 2;64(21):2305-7.

4. Stewart S., Hart C.L., Hole D.J., McMurray J.J. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/ Paisley study. Heart 2001; 86: 516–521.

5. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370–2375.

6. Nieuwlaat R., Capucci A., Camm A.J., et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005; 26: 2422–2434.

7. Nabauer M., Gerth A., Limbourg T., et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423–434.

8. Fox C.S., Parise H., D’Agostino R.B. Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004; 291: 2851–2855.

9. Kirchhof P., Bax J., Blomstrom-Lundquist C., et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘Research perspectives in AF’. EurHeartJ 2009; 30: p2969–2977c.

10. Щербакова Н.В., Мешков А.Н., Бойцов С.А. Применение метода секвенированияэкзомов для диагностики предрасположенности к комплексным заболеваниям в профилактической медицине. Кардиоваск. Тер. и проф. 2013; 12(6): 24-28. [Shcherbakova N.V., Meshkov A.N., Boytsov S.A. Exome sequencing and the diagnostics of complex disease predisposition in preventive medicine. Cardiovasc. Ther. Prof. 2013; 12(6): 24-28 (in Russ.)]. DOI: нет.

11. Мясников Р.П., Щербакова Н.В., Куликова О.В., Мешков А.Н., Харлап М.С., Киселева А.В., Жарикова А.А., Дадали Е.Л., Семенова Н.А., Корецкий С.Н., Благова О.В., Мершина Е.А., Синицын В.Е., Драпкина О.М., Бойцов С.А. Мутациягена DES в семье пробанда с миофибриллярной миопатией и развитием некомпактной кардиомиопатии, приведшей к трансплантации сердца. Российский кардиологический журнал 2017; 10 (150): 9–16. [Myasnikov R.P., Shcherbakova N.V., Kulikova О.V., Meshkov А.N., Kharlap M.S., Kiseleva А.V., Zharikova А.А., Dadali Е.L., Semenova N.А., Koretsky S.N., Blagova О.V., Mershina Е.А., Sinitsyn V.Е., Drapkina О.М., Boytsov S.А. DES gene mutation in a family of proband with myofibrillary myopathy and non-compaction cardiomyopathy, resulted in cardiac transplantation. Russ J Cardiol

12. , 10 (150): 9–16 (in Russ.)] DOI: http://dx.doi.org/10.15829/1560-4071-2017-10-9-16

13. Акрамова Э.Г. Характеристика нарушений ритма сердца у больных хронической обструктивной болезнью легких. Клиническая медицина. 2013; 91(2): 41-44. [Akramova E.G. Characteristic of cardiac rhythm disturbances in patients with chronic obstructive pulmonary disease. Clinicalmedicine. 2013; 91(2): 41-44. (inRuss.)] DOI: нет.

14. Апарина О.П., Чихирева Л.Н., Миронова Н.А., Миронова Е.С., Бакалов С.А. Роль структурно-функциональных изменений предсердий в развитии и прогрессировании фибрилляции предсердий. Терапевтический архив. 2014;86 (1):71-77. [AparinaOP, ChikhirevaLN, MironovaNA, MironovaES, BakalovSA. Role of atrial structural and functional changes in the development and progression of atrial fibrillation TerArkh. 2014;86 (1):71-77. (InRuss.).] DOI: нет.

15. Акрамова Э.Г. Клиническая значимость продольной деформации левого желудочка при ишемической болезни сердца и некоронарогенной патологии. Казанский мед. ж. 2019; 100 (2): 295–302. [Akramova E.G. Clinical significance of left ventricular longitudinal deformation in coronary heart disease and non-coronary pathology. Kazan medical journal. 2019; 100 (2): 295–302 (in Russ.)]. DOI: 10.17816/ KMJ2019-295.

16. Родионова Е.С., Миронова Н.А., Апарина О.П., Рогова М.М., Зыков К.А., Голицын С.П. Роль аутоиммунных реакций в развитии нарушений ритма и проводимости сердца // Терапевтический архив. 2012; 4: 74–78. [Rodionova E.S., Mironova N.A., Rogova M.M. Rogova M.M., Zykov K.A., Golitsyn S.P. Role of autoimmune reactions in development of cardiac arrhythmia and conduction disturbances. Terapevticheskiyarkhiv. 2012; 4: 74–78 (in Russ.)]. УДК: 616.12-008.318-092:612.017.1. DOI: нет.

17. Костюкевич М.В., Зыков К.А., Миронова Н.А., Агапова О.Ю., Шевелев А.Я., Ефремов Е.Е., Власик Т.Н., Голицын С.П. Роль аутоантител к ß1-адренорецептору при сердечно-сосудистых заболеваниях. Кардиология. 2016; 56 (12): 82-91. [Kostyukevich M.V., Zykov K.A., Mironova N.A., Agapova O.Y., Shevelev A.Y., Efremov E.E., Vlasik T.N., Golitsyn S.P. Role of Autoantibodies Against ß1-Adrenergic Receptor in Cardiovascular Disease. Kardiologiia. 2016; 56 (12): 82-91 (In Russ.)] DOI: 10.18565/cardio.2016.12.82-91

18. Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial fibrillation — a translational appraisal. Physiol Rev 2010

19. Миронова Е.С., Миронов Н.Ю., Миронова Н.А., Новиков П.С., Новиков И.А., Лайович Л.Ю., Майков Е.Б., Голицын С.П. Электрофизиологические параметры сердца и результаты противоаритмического лечения у больных с пароксизмальной формой фибрилляции предсердий, идиопатической и в сочетании с гипертонической болезнью. Кардиология. 2019;59(8):39-46. https://doi.org/10.18087/ cardio.2019.8.n644 [Mironova E.S., Mironov N.Y., Mironova N.A., Novikov P.S., Novikov I.A., Layovich L.Y., Maykov E.B., Golitsyn S.P. Electrophysiological Cardiac Parameters and Results of Antiarrhythmic Treatment in Patients with Paroxysmal Atrial Fibrillation (Lone and Associated with Arterial Hypertension). Kardiologiia. 2019;59(8):39-46. (In Russ.)] https://doi.org/10.18087/cardio.2019.8.n644

20. Camm A.J., Kirchhof P., Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). EurHeartJ 2010; 31: 2369-2429

21. Сулимов В.А., Голицин В.П., Панченко Е.П. и др. Диагностика и лечение фибрилляции предсердий. Рекомендации РКО, ВНОА, АССХ. Москва, 2013.

22. Миронов Н.Ю., Лайович Л.Ю., Миронова Е.С. и др. Новые достижения в диагностике и лечении фибрилляции предсердий: от экспериментальных исследований до повседневной клинической практики. Терапевтический архив. 2019; 91 (6): 11–18]. DOI: 10.26442/00403660.2019.06.000295 [Mironov N.Yu., Laiovich L.Yu., Mironova E.S., et al. Recent advances in diagnosis and management of atrial fibrillation. Therapeutic Archive. 2019; 91 (6): 11–18. (In Russ.)] DOI:10.26442/00403660.2019.06.000295.

23. Уцумуева М.Д., Миронова Н.А., Каштанова С.Ю., Стукалова О.В. Возможности магнитно-резонансной томографии сердца при отборе кандидатов на сердечную ресинхронизирующую терапию. Медицинская визуализация. 2018;(4):20-31. https://doi.org/10.24835/1607-0763-2018-4-20-31 [Utsumueva M.D., Mironova N.A., Kashtanova S.Y., Stukalova O.V. Possibilities of cardiac magnetic resonance in selection of candidates for cardiac resynchronization therapy. Medical Visualization. 2018;(4):20-31. (In Russ.)] https://doi.org/10.24835/1607-0763-2018-4-20-31

24. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 2007;28:2803–2817.

25. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREventionoFthromboemolic events — European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6–14.

26. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G. Improved outcomes with European Society of Cardiology guidelineadherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace 2015;17:1777–1786.

27. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127: 634–640.

28. Gulamhusein S., Ko P., Carruthers S.G., Klein G.J. Acceleration of the ventricular response during atrial fibrillation in the Wolff-ParkinsonWhite syndrome after verapamil. Circulation 1982; 65: 348–354.

29. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD, Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: an individual-patient data metaanalysis. Lancet 2014;384:2235–2243.

30. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946–952.

31. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the longterm risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/ Paisley study. Am J Med 2002;113:359–364.

32. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term casecontrol study. Eur Heart J 2013;34:1061–1067.

33. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004;25:1385–1394.

34. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, Kottkamp H. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 2005; 112:307–313.

35. Arya A., Hindricks G., Sommer P., et al. Longterm results and the predictors of outcome of catheter ablation of atrial fibrillation using steerable sheath catheter navigation after single procedure in 674 patients. Europace 2010; 12: 173–180.

36. Осмоловская Ю.Ф., Романова Н.В., Жиров И.В., Терещенко С.Н. Эпидемиология и особенности терапии хронической сердечной недостаточности в сочетании с фибрилляцией предсердий. Медицинский Совет. 2016;(10):93-97. https://doi.org/10.21518/2079-701X-2016-10-93-97 [Osmolovskaya Y.F., Romanova N.V., Zhirov I.V., Tereschenko s.n. Epidemiology and management of heart failure patients with atrial fibrillation. Medical Council. 2016;(10):93-97. (In Russ.)] https://doi.org/10.21518/2079-701X-2016-10-93-97

37. Connolly S.J., Eikelboom J., Joyner C., et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.

38. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–1912.

39. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, Mahaffey KW, Gersh BJ, Hylek E, Naccarelli G, Go AS, Reiffel J, Chang P, Peterson ED, Piccini JP. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J 2014;167:735–742.e2.

40. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, RichMW, Radford MJ. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151:713–719.

41. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975–983.

42. Bajaj NS, Parashar A, Agarwal S, Sodhi N, Poddar KL, Garg A, Tuzcu EM, Kapadia SR. Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a systematic review and analysis of observational studies. JACC CardiovascInterv 2014;7:296–304.

43. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014;45:520–526.

44. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093–1100.

45. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–1510.

46. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.

47. Lewalter T, Kanagaratnam P, Schmidt B, Rosenqvist M, Nielsen-Kudsk JE, Ibrahim R, Albers BA, Camm AJ. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. Europace 2014;16:626–630.

48. Bartel T, Erbel R, Acute Trial Investigators. Transoesophageal echocardiography for immediate and safe cardioversion in patients with atrial fibrillation. Eur Heart J 2001;22:2041–2044.

49. Conti A, Canuti E, Mariannini Y, Viviani G, Poggioni C, Boni V, Pini R, Vanni S, Padeletti L, Gensini GF. Clinical management of atrial fibrillation: early interventions, observation, and structured follow-up reduce hospitalizations. Am J Emerg Med. 2012 Nov;30(9):1962-9. doi: 10.1016/j.ajem.2012.04.022. Epub 2012 Jul 15.

50. Wilber D.J., Pappone C., Neuzil P., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303: 333–340.

51. Stewart S1, Ball J2, Horowitz JD3, Marwick TH4, Mahadevan G3, Wong C5, Abhayaratna WP6, Chan YK7, Esterman A8, Thompson DR2, Scuffham PA9, Carrington MJ7. Standard versus atrial fibrillationspecific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. Lancet. 2015 Feb 28;385(9970):775-84. doi: 10.1016/S0140-6736(14)61992-9. Epub 2014 Nov 17.

52. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.

53. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J 2014;35:1205–1214.

54. Weir MR, Kreutz R. Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. Mayo Clin Proc. 2018 Oct;93(10):1503-1519. doi: 10.1016/j.mayocp.2018.06.018.

55. Steinberg JS, Varma N, Cygankiewicz I, Aziz P, Balsam P, Baranchuk A, Cantillon DJ, Dilaveris P, Dubner SJ, El-Sherif N, Krol J, Kurpesa M, La Rovere MT, Lobodzinski SS, Locati ET, Mittal S, Olshansky B, Piotrowicz E, Saxon L, Stone PH, Tereshchenko L, Turakhia MP, Turitto G, Wimmer NJ, Verrier RL, Zareba W, Piotrowicz R. 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. Ann Noninvasive Electrocardiol. 2017 May;22(3). doi: 10.1111/anec.12447.

56. Scirica BM, Belardinelli L, Chaitman BR, Waks JW, Volo S, KarwatowskaProkopczuk E, Murphy SA, Cheng ML, Braunwald E, Morrow DA. Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Europace 2015;17:32–37.

57. .Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, ZarebaW, Rosero S, Kowey P, HARMONY Investigators. The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic Synergism. CircArrhythmElectrophysiol 2015;8:1048–1056.

58. Balik M, Matousek V, Maly M, Brozek T. Management of arrhythmia in sepsis and septic shock. Anaesthesiol Intensive Ther. 2017;49(5):419-429. doi: 10.5603/AIT.a2017.0061. Epub 2017 Nov 18.

59. Dorian P., Guerra P.G., Kerr C.R., et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. CircArrhythmElectrophysiol 2009; 2: 218–224.

60. Shamiss Y, Khaykin Y, Oosthuizen R, Tunney D, Sarak B, Beardsall M, Seabrook C, Frost L, Wulffhart Z, Tsang B, Verma A. Dofetilide is safe and effective in preventing atrial fibrillation recurrences in patients accepted for catheter ablation. Europace 2009;11:1448–1455.

61. Mazzaferri EL, Reynolds JC, Young RL, Thomas CN, Parisi AF. Propranolol as primary therapy for thyrotoxicosis. Arch Intern Med. 1976 Jan;136(1):50-6.

62. Simopoulos V, Tagarakis GI, Daskalopoulou SS, Daskalopoulos ME, Lenos A, Chryssagis K, Skoularingis I, Molyvdas PA, Tsilimingas NB, Aidonidis I. Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. Angiology 2014; 65: 294–297.

63. Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014;16:973–979.

64. Nieuwlaat R., Hohnloser S.H., Connolly S.J. Effects of dronedarone in patients with permanent atrial fibrillation during the ATHENA study [abstract]. Eur Heart J 2011; 32: 618.

65. Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron B, McGrath L, Innes G. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness. AcadEmerg Med. 2013 Mar;20(3):222-30. doi: 10.1111/acem.12091.

66. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation. Am J Cardiol. 2013 Jan 15;111(2):225-30. doi: 10.1016/j.amjcard.2012.09.020. Epub 2012 Oct 27.

67. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, Rienstra M, Van den Berg MP, Van Gelder IC; RACE II Investigators. Digoxin in patients with permanent atrial fibrillation: data from the RACE II study. Heart Rhythm. 2014 Sep;11(9):1543-50. doi: 10.1016/j.hrthm.2014.06.007. Epub 2014 Jun 9.

68. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010 Apr 15;362(15):1363-73. doi: 10.1056/NEJMoa1001337. Epub 2010 Mar 15.

69. Sellers TD, Bashore TM, Gallagher JJ. Digitalis in the pre-excitation syndrome. Analysis during atrial fibrillation. Circulation. 1977; 56:260–7.

70. Sheinman BD, Evans T. Acceleration of ventricular rate by fibrillation associated with the Wolff-Parkinson-White syndrome. Br Med J (Clin Res Ed). 1982; 285:999–1000.

71. Boriani G, Biffi M, Frabetti L, et al.. Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. AmHeartJ. 1996; 131:1214–6.

72. Миронов Н.Ю., Голицын С.П., Соколов С.Ф., Майков Е.Б., Шлевков Н.Б., Юричева Ю.А., Мареев Ю.В., Розенштраух Л.В., Чазов Е.И. Электрофизиологические эффекты и противоаритмическая активность нового отечественного антиаритмического препарата III класса ниферидила у больных пароксизмальными наджелудочковыми тахикардиями. Экспериментальная и клиническая фармакология. 2012; 75 (10): 16-21. [Mironov N.Yu., Golitsyn S.P., Sokolov S.F., Maikov E.B., Shlevkov N.B., Yuricheva Yu.A., Mareev Yu.V., Rozenshtraukh L.V., Chazov E.I. Electrophysiological Effects and Antiarrhythmic Activity of Novel Domestic Class III Antiarrhythmogenic Drug Niferidil Administered in Patients with Paroxismal Supraventricular Tachycardia. Experimental and clinical pharmacology. 2012; 75 (10): 16-21. (in Russ.)]. Doi нет

73. Юричева Ю.А., Соколов С.Ф., Голицын С.П., Миронов Н.Ю., Ривин А.Е., Берман М.В., Шубик Ю.В., Зотова И.В., Затейщиков Д.А., Болотова М.Н., Розенштраух Л.В., Чазов Е.И. Новый антиаритмический препарат III класса ниферидил как эффективное средство восстановления синусового ритма при персистирующей форме мерцательной аритмии. Вестник аритмологии. 2012; 70: 32-43. [Yuricheva Yu.A., Sokolov S.F., Golitsyn S.P., Mironov N.Yu., Rivin A.E., Berman M.V., ShubikYu.V., Zotova I.V., Zateyshchikov D.A., Bolotova M.N., Rozenshtraukh L.V., Chazov E.I. A novel III class antiarryhthmic, niferidil, as an effective medication for the sinus rhythm recovery in patients with persistent atrial fibrillation. Journalofarrhythmology. 2012; 70: 32-43. (inRuss.)] Doi нет

74. Миронов Н.Ю., Влодзяновский В.В., Юричева Ю.А., Соколов С.Ф., Голицын С.П., Розенштраух Л.В., Чазов Е.И. Проспективное рандомизированное исследование эффективности и безопасности

75. электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 1: методология исследования и оценка эффективности. Рациональная фармакотерапия в кардиологии. 2018;. 14(5): 664-669. [MironovN.Yu., Vlodzyanovskiy V.V., YurichevaYu.A., Sokolov S.F., Golitsyn S.P., Rosenstraukh L.V., Chazov E.I. Safety and effectiveness of electrical and pharmacological cardioversion in persistent atrial fibrillation. Part I: study rationale, design and assessment of effectiveness. Ration. Pharmacother. Cardiol. 2018; 14(5): 664-669. (inRuss.)] DOI: 10.20996/1819-6446-2018-14-5-664-669

76. Миронов Н.Ю., Влодзяновский В.В., Юричева Ю.А., Соколов С.Ф., Голицын С.П., Розенштраух Л.В., Чазов Е.И. Проспективноерандомизированное исследование эффективности и безопасности электрической и медикаментозной кардиоверсии при персистирующей фибрилляции предсердий. Часть 2: оценка безопасности. Рациональная фармакотерапия в кардиологии. 2018; 14(6): 826-830. [MironovN.Yu., Vlodzyanovskiy V.V., Yuricheva Yu.A., Sokolov S.F., Golitsyn S.P., Rosenstraukh L.V., Chazov E.I. Safety and effectiveness of electrical and pharmacological cardioversion in persistent atrial fibrillation. Part 2: assessment of safety. Ration. Pharmacother. Cardiol. 2018; 14(6): 826-830 (in Russ.)]. DOI: 10.20996/1819-6446-2018-14-6-826-830

77. Mironov N, Vlodzyanovsky V, Yuricheva Yu, Sokolov S, Golitsyn S, Rosenstraukh L, Chazov E. Safety and effectiveness of pharmacological conversion and direct current cardioversion in persistent atrial fibrillation: results of randomized trial. J Am CollCardiol Volume 73, Issue 9 Supplement 1, March 2019 DOI: 10.1016/S0735-1097(19)30906-4

78. Conde D, Costabel JP, Aragon M, Lambardi F, Klein A, Corrales Barbosa A, Trivi M, Giniger A. Propafenone versus vernakalant for conversion of recent-onset atrial fibrillation. CardiovascTher. 2013 Dec;31(6):377-80. doi: 10.1111/1755-5922.12036.

79. Hern ndez-Madrid A, Svendsen JH, Lip GY, Van Gelder IC, Dobreanu D, Blomstrom-Lundqvist C; Scientific Initiatives Committee, European Heart Rhythm Association (EHRA). Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. Europace. 2013 Jun;15(6):915-8. doi: 10.1093/europace/eut143.

80. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003;87:121–128.

81. Andrade JG, MacGillivray J, Macle L, Yao RJR, Bennett M, Fordyce CB, Hawkins N, Krahn A, Jue J, Ramanathan K, Tsang T, Gin K, Deyell MW. Clinical effectiveness of a systematic «pill-in-the-pocket» approach for the management of paroxysmal atrial fibrillation. Heart Rhythm. 2018 Jan;15(1):9-16. doi: 10.1016/j.hrthm.2017.10.002.

82. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am CollCardiol. 2003 Jan 15;41(2):255-62.

83. Schneider MP, Hua TA, B hm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am CollCardiol. 2010 May 25;55(21):2299-307. doi: 10.1016/j.jacc.2010.01.043.

84. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008 Jan-Feb;15(1):36-43. doi: 10.1097/MJT.0b013e31804beb59.

85. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study. Eur Heart J. 2014 May;35(18):1205-14. doi: 10.1093/eurheartj/eht507. Epub 2013 Dec 17.

86. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003 Dec;24(23):2090-8.

87. Haissaguerre M., Jais P., Shah D.C., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659–666.

88. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, Laroche C, Anselme F, Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse GH, Perez-Villacastin J, Riahi S, Taborsky M, Theodorakis G, Trines SA, Atrial Fibrillation Ablation Pilot Study Investigators. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014;35: 1466–1478.

89. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528–606.

90. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V, Brugada J, Camm J, Chen PS, Chen SA, Chung MK, Nielsen JC, Curtis AB, Davies DW, Day JD, d’Avila A, de Groot NMSN, Di Biase L, Duytschaever M, Edgerton JR, Ellenbogen KA, Ellinor PT, Ernst S, Fenelon G, Gerstenfeld EP, Haines DE, Haissaguerre M, Helm RH, Hylek E, Jackman WM, Jalife J, Kalman JM, Kautzner J, Kottkamp H, Kuck KH, Kumagai K, Lee R, Lewalter T, Lindsay BD, Macle L, Mansour M, Marchlinski FE, Michaud GF, Nakagawa H, Natale A, Nattel S, Okumura K, Packer D, Pokushalov E, Reynolds MR, Sanders P, Scanavacca M, Schilling R, Tondo C, Tsao HM, Verma A, Wilber DJ, Yamane T. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017 Oct;14(10):e275-e444. doi: 10.1016/j.hrthm.2017.05.012. Epub 2017 May 12.

91. Wilber D.J., Pappone C., Neuzil P., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303: 333–340.

92. Calkins H., Reynolds M.R., Spector P., et al. Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. CircArrhythmElectrophysiol 2009; 2: 349–361.

93. Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005; 293: 2634–2640.

94. Wazni O.M., Marrouche N.F., Martin D.O., et al. Radiofre-quency ablation vs antiarrhythmic drugs as firstline treatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005; 293: 2634–2640.

95. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, B nsch D; CASTLE-AF Investigators. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018 Feb 1;378(5):417-427. doi: 10.1056/NEJMoa1707855.

96. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A. Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial. Circulation. 2016 Apr 26;133(17):1637-44. doi: 10.1161/CIRCULATIONAHA.115.019406. Epub 2016 Mar 30.

97. Prabhu S, Taylor AJ, Costello BT, Kaye DM, McLellan AJA, Voskoboinik A, Sugumar H, Lockwood SM, Stokes MB, Pathik B, Nalliah CJ, Wong GR, Azzopardi SM, Gutman SJ, Lee G, Layland J, Mariani JA, Ling LH, Kalman JM, Kistler PM. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am CollCardiol. 2017 Oct 17;70(16):1949-1961. doi: 10.1016/j.jacc.2017.08.041. Epub 2017 Aug 27.

98. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am CollCardiol. 2019 Jan 21. pii: S0735-1097(19)30209-8. doi: 10.1016/j.jacc.2019.01.011. [Epub ahead of print]

99. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Moretz K, Poole JE, Mascette A, Rosenberg Y, Jeffries N, Al-Khalidi HR, Lee KL; CABANA Investigators. Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) Trial: Study Rationale and Design. Am Heart J. 2018 May;199:192-199. doi: 10.1016/j.ahj.2018.02.015. Epub 2018 Mar 7.

100. Bilchick KC, Mealor A, Gonzalez J, et al. Effectiveness of Integrating Delayed Computed Tomography Angiography Imaging for Left Atrial Appendage Thrombus Exclusion into the Care of Patients Undergoing Ablation of Atrial Fibrillation. Heart Rhythm. 2016 January; 13(1): 12–19.

101. Teunissen C, Habets J, Velthuis BK, Cramer MJ,•Loh P. Double-contrast, single-phase computed tomography angiography for ruling out left atrial appendage thrombus prior to atrial fibrillation ablation. Int J Cardiovasc Imaging, 2017, 33(1): 121-128.

102. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardio-version for acute atrial fibrillation and thromboembolic complications. JAMA 2014;312:647 – 649.

103. Kuck KH1, Brugada J1, Fürnkranz A1, Metzner A1, Ouyang F1, Chun KR1, Elvan A1, Arentz T1, Bestehorn K1, Pocock SJ1, Albenque JP1, Tondo C1; FIRE AND ICE Investigators. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45. doi: 10.1056/NEJMoa1602014. Epub 2016 Apr 4.

104. Verma A1, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P; STAR AF II Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015 May 7;372(19):1812-22. doi: 10.1056/NEJMoa1408288.

105. Buch E, Share M, Tung R, Benharash P, Sharma P, Koneru J, Mandapati R, Ellenbogen KA, Shivkumar K. Long-term clinical outcomes of focal impulse and rotor modulation for treatment of atrial fibrillation: A multicenter experience. Heart Rhythm. 2016 Mar;13(3):636-41. doi: 10.1016/j.hrthm.2015.10.031. Epub 2015 Oct 21.

106. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA, ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 2010; 303:333–340.

107. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, Laroche C, Anselme F, Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse GH, Perez-Villacastin J, Riahi S, Taborsky M, Theodorakis G, Trines SA, Atrial Fibrillation Ablation Pilot Study Investigators. The atrial fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014;35: 1466–1478.

108. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, TorpPedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360:668–678.

109. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014;160:760–773.

110. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE 2013;36:122–133.

111. Tischenko A, Fox DJ, Yee R, Krahn AD, Skanes AC, Gula LJ, Klein GJ. When should we recommend catheter ablation for patients with the Wolff-Parkinson-White syndrome? CurrOpinCardiol 2008;23:32–37.

112. Kibos A, Deharo JC, Adoubi A, Assouan X, Djianeb P. [Clinical and electrophysiological study of asymptomaticWolff-Parkinson-White syndrome]. Ann CardiolAngeiol (Paris) 2007;56:237–240.

113. Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G, Gulletta S, Mazzone P, Tortoriello V, Pappone A, Dicandia C, Rosanio S. A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 2003;349:1803–1811.

114. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length. J Am CollCardiol 1990;16: 1408–1414.

115. Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, Larsen TB. Atrial flutter and thromboembolic risk: a systematic review. Heart 2015;101: 1446–1455.

116. Bertaglia E, Zoppo F, Bonso A, Proclemer A, Verlato R, Coro L, Mantovan R, D’Este D, Zerbo F, Pascotto P. Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course and predictors of atrial fibrillation occurrence. Heart 2004;90:59–63.

117. Seara JG, Roubin SR, GudeSampedro F, Barreiro VB, Sande JM, Manero MR, Grandio PC, Alvarez B, Juanatey JG. Risk of atrial fibrillation, stroke, and death after radiofrequency catheter ablation of typical atrial flutter. Clin Res Cardiol 2014;103:543–552.

118. Bronis K, Metaxa S, Koulouris S, Manolis AS. Vernakalant: review of a novel atrial selective antiarrhythmic agent and its place in current treatment of atrial fibrillation. Hosp Chronicles 2012;7:171–181.

119. Schmieder S, Ndrepepa G, Dong J, Zrenner B, Schreieck J, Schneider MA, Karch MR, Schmitt C. Acute and long-term results of radiofrequency ablation of common atrial flutter and the influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J 2003;24:956–962.

120. Bandini A, Golia P, Caroli E, Biancoli S, Galvani M. Atrial fibrillation after typical atrial flutter ablation: a long-term follow-up. J Cardiovasc Med (Hagerstown) 2011; 12:110–115.

121. Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clinical outcomes after catheter ablation of atrial flutter. PLoS One 2014;9:e100509.

122. Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press (US); 2001.

123. N M Al-Saady, O A Obel, A J Caam “Left atrial appendage: structure, function, and role in thromboembolism” Heart 1999; 82:547-554.

124. Leung DY, Davidson PM, Cranney GB, Walsh WF “Tromboembolic risks of left atrial thrombus detected by transesophageal echocardiogram” Am J Cardiol 1997 Mar 1;79 (5):626-9.

125. Fatkin D, Kelly RP, Feneley MP “Relation between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo” JACC 1994;23:961-9

126. Goldman ME, Pearce LA, Hart RG Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (The Stroke Prevention in Atrial Fibrillation [SPAF-III] study J Am SocEchocardiogr 1999 Dec; 12(12):1080-7

127. Mitusch R, Siemens HJ, Garbe M et al “Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy” ThrombHaemost 1996 Feb;75(2):219-23

128. Neyer J., et al. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation 2007; 115:69–171.

129. Скворцова В.И. Артериальная гипертония и цереброваскулярные нарушения. Руководство по артериальной гипертонии/ Под редакцией Чазова Е.И., Чазовой И.Е.- М.: Меди Медика, 2005. – 784 с

130. Суслина З.А., Варакин Ю.Я. Профилактика нарушений мозгового кровообращения. Очерки ангионеврологии / Под редакцией Суслиной З.А. – М.: Атмосфера, 2005. – 368 с

131. HartR.G., PearceL.A., AguilarM.I. “Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation” Ann Intern Med 2007;146:857–867.

132. Connolly S, Eikelboom J, Joyner C et al. Apixaban in Patients with Atrial Fibrillation. New England Journal of Medicine. 2011;364(9):806-817. DOI: 10.1056/nejmoa1007432

133. ACTIVE Writing Group of the ACTIVE Investigators. “Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial” Lancet 2006;367:1903–1912.

134. Connolly S.J., Pogue J., EikelboomJ,.et al ACTIVE W Investigators “Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range” Circulation 2008;118:2029–2037.

135. Apostolakis S., Sullivan R.M., Olshansky B., Lip G.Y. “Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score” Chest 2013;144:1555–1563

136. Connolly S.J., Ezekowitz M.D., Yusuf S. et al “Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial” N Engl J Med 2010;363:1875–1876.

137. Patel M.R., Mahaffey K.W., Garg J. et al ROCKET AF Investigators. “Rivaroxaban versus warfarin in nonvalvular atrial fibrillation” N Engl J Med 2011;365:883–891.33.319

138. Granger C.B., Alexander J.H., McMurray J.J., et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–92.

139. Friberg L., Rosenqvist M., Lip G.Y. “Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study” Eur Heart J 2012;33:1500–1510.

140. Lip G, Windecker S, Huber K et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35(45):3155-3179. DOI:10.1093/eurheartj/ehu298

141. Blackshear, J.L. & Odell, J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann. Thorac. Surg. 1996; 61, 755–759

142. Chatterjee, S., Alexander, J. C., Pearson, P. J. & Feldman, T. Left atrial appendage occlusion: lessons learned from surgical and transcatheter experiences. Ann. Thorac. Surg. 2011; 92, 2283–2292

143. Salzberg, S.P. et al. Left atrial appendage clip occlusion: early clinical results. J. Thorac. Cardiovasc. Surg. 2010; 139, 1269–1274

144. Blackshear, J.L. et al. Thoracoscopicextracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. J. Am. Coll. Cardiol. 2003; 42, 1249–1252

145. Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing concomitant cardiac surgery. JAMA. 2018;319:365-74

146. Melduni RM, Schaff HV, Lee H-C, et al. Impact of left atrial appendage closure during cardiac surgery on the occurrence of early postoperative atrial fibrillation, stroke, and mortality: a propensity score-matched analysis of 10 633 patients. Circulation. 2017;135:366-78

147. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke Prevention in atrial fibrillation: a patientlevel meta-analysis. J Am CollCardiol. 2015;65:2614-23

148. Tzikas A, Holmes DR Jr, Gafoor S, et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace. 2016;19(1):4–15. doi:10.1093/europace/euw141

149. Wang, Y. A. N. et al. Left atrial appendage studied by computed tomography to help planning for appendage closure device placement. J. Cardiovasc. Electrophysiol. 2010; 21, 973–982

150. Holmes D, Reddy V, Turi Z, Doshi S, Sievert H, Buchbinder M et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534–42

151. Tzikas A, Shakir S, Gafoor S, Omran H, Berti S, Santoro G et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 2016;11:1170–9

152. Reddy VY, M bius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am CollCardiol. 2013;61:2551-6

153. Reddy VY, Gibson DN, Kar S, et al. Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am CollCardiol. 2017;69:253-61

154. Lemesle G, Ducrocq G, Elbez Y et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. ClinCardiol. 2017 Oct;40(10):932-939. doi: 10.1002/clc.22750. Epub 2017 Jul 10.

155. Sørensen R, Hansen M, Abildstrom S et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. The Lancet. 2009;374(9706):1967-1974. DOI:10.1016/s0140-6736(09)61751-7

156. Hansen M, Sørensen R, Clausen M et al. Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation. Arch Intern Med. 2010;170(16). DOI: 10.1001/archinternmed.2010.271

157. Valgimigli M, Bueno H, Byrne RA, et al ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.

158. Steffel J, Verhamme P, Potpara T et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330-1393. DOI:10.1093/eurheartj/ehy136

159. Gibson C, Mehran R, Bode C et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. New England Journal of Medicine. 2016;375(25):2423-2434. DOI:10.1056/nejmoa1611594

160. Cannon C, Bhatt D, Oldgren J et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine. 2017;377(16):1513-1524. DOI:10.1056/nejmoa1708454

161. Lopes RD, Heizer G, Aronson R et al AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.

162. Kakkar AK, Mueller I, Bassand JP et al «International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD)» AHJ 2012; 163(1):13-19

163. Ruff C.T., Giugliano R.P., Braunwald E. et al Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. J Am CollCardiol. 2014 Aug 12;64(6):576-84. doi: 10.1016/j.jacc.2014.05.028.

164. Pollack C.V. Jr., Reilly P.A., van Ryn J., et al. Idarucizumab for dabigatran reversal – Full cohort analysis. N. Engl. J. Med. 2017; 377: 431–41.

165. Vosko M.R., BocksruckerС., Drwiła R., et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran treated. J. Thromb. Thrombolysis. 2017;

166. Deborah M. Siegal, M.D., John T. Curnutte, M.D., Ph.D., Stuart J. Connolly, M.D., et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity N Engl J Med 2015; 373:2413-2424 DOI: 10.1056/NEJMoa151099143: 306–317.

167. SigrunHalvorsen, Robert F. Storey, Bianca Rocca, et a. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis, European Heart Journal, Volume 38, Issue 19, 14 May 2017, Pages 1455–1462, https://doi.org/10.1093/eurheartj/ehw454

168. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, Hartikainen JE. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am CollCardiol 2013;62: 1187–1192

169. Berger M1, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am J Cardiol. 1998 Dec 15;82(12):1545-7, A8.

170. Nuotio I, Hartikainen JE, Grönberg T et al Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014 Aug 13;312(6):647-9. doi: 10.1001/jama.2014.3824.

171. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015 Oct;17(10):1467-507. doi: 10.1093/europace/euv309. Epub 2015 Aug 31

172. A Goette, H Heidbuchel. Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation. Arrhythmia & Electrophysiology Review 2017;6(2):50–4. DOI: 10.15420/aer.2017:3:2

173. Renda G, Zimarino M, Ricci F1, et al Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. Am J Med. 2016 Oct;129(10):1117-1123.e2. doi: 10.1016/j.amjmed.2016.05.007. Epub 2016 Jun 2.

174. Weigner MJ, Thomas LR, Patel U et al Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. Am J Med. 2001 Jun 15;110(9):694-702.

175. Wu LA, Chandrasekaran K, Friedman PA, et al Safety of expedited anticoagulation in patients undergoing transesophageal echocardiographic-guided cardioversion. Am J Med. 2006 Feb;119(2):142-6.

176. Jaber WA, Prior DL, Thamilarasan M, et al Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: A transesophageal echocardiographic study. Am Heart J. 2000 Jul;140(1):150-6.

177. Barysienė J, Žebrauskaitė A, Petrikonytė D, et al. Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion. BMC CardiovascDisord. 2017 Feb 23;17(1):67. doi: 10.1186/s12872-017-0503-8

178. Weigner MJ, Caulfield TA, Danias PG, et al Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997 Apr 15;126(8):615-20

179. Ezekowitz MD, Pollack CV Jr, Halperin JL5 et al Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.

180. Fauchier L, Cinaud A, Brigadeau F, et al. Left Atrial Appendage Closure in Atrial Fibrillation. J Am CollCardiol. 2018 Dec 4;72(22):2806-2807. doi: 10.1016/j.jacc.2018.08.2196.

181. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805–1811

182. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017;376:1627–1636.

183. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. European Heart Journal, Volume 39, Issue 32, Pages 2942–2955, https://doi.org/10.1093/eurheartj/ehy176

184. Hohnloser SH, Camm J, Cappato R, et al. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATEAF trial. Eur Heart J. 2019 Apr 11. pii: ehz190. doi: 10.1093/eurheartj/ehz190. [Epub ahead of print]

185. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003;123:676–682

186. Di BiaseL, Burkhardt JD,Santangeli P, et al. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial. Circulation 2014;129:2638–2644

187. Franz-Josef Neumann, Miguel Sousa-Uva, Anders Ahlsson, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization, European Heart Journal, Volume 40, Issue 2, 07 January 2019, Pages 87–165, https://doi.org/10.1093/eurheartj/ehy394


Для цитирования:


Голицын С.П., Панченко Е.П., Кропачева Е.С., Лайович Л.Ю., Майков Е.Б., Миронов Н.Ю., Шахматова О.О. ДИАГНОСТИКА И ЛЕЧЕНИЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ. Евразийский кардиологический журнал. 2019;(4):4-85.

For citation:


Golitsyn S.P., Panchenko E.P., Kropacheva E.S., Layovich L.Yu., Maikov E.B., Mironov N.Yu., Shakhmatova O.O. EURASIAN CLINICAL RECOMMENDATIONS ON DIAGNOSIS AND TREATMENT OF ATRIAL FIBRILLATION. Eurasian heart journal. 2019;(4):4-85.

Просмотров: 139


Creative Commons License
Контент доступен под лицензией BY NC ND.


ISSN 2225-1685 (Print)
ISSN 2305-0748 (Online)